Cargando…

Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease driven by genetic and environmental factors. MicroRNAs (miRNAs) serve as pleiotropic post‐transcriptional regulators of cellular pathways. Although several miRNAs have been associated with NAFLD and fibrosis, there are limited studi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezaz, Ghideon, Trivedi, Hirsh D., Connelly, Margery A., Filozof, Claudia, Howard, Kellie, L.Parrish, Mark, Kim, Misung, Herman, Mark A., Nasser, Imad, Afdhal, Nezam H., Jiang, Z. Gordon, Lai, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193128/ https://www.ncbi.nlm.nih.gov/pubmed/32363318 http://dx.doi.org/10.1002/hep4.1501

Ejemplares similares

A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease
por: Danford, Christopher J., et al.
Publicado: (2018)

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
por: Tapper, Elliot B., et al.
Publicado: (2016)

Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity
por: Sandhu, Bynvant, et al.
Publicado: (2019)

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
por: Vieira Barbosa, Joana, et al.
Publicado: (2021)

An Algorithmic Approach to NAFLD Screening: From PCP to Specialist
por: Trivedi, Hirsh D.
Publicado: (2020)

Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
por: Ezaz, Ghideon, et al.
Publicado: (2014)

Extra-pancreatic complications, especially hemodialysis predict mortality and length of stay, in ICU patients admitted with acute pancreatitis
por: Kothari, Darshan, et al.
Publicado: (2018)

Dual Role of MicroRNAs in NAFLD
por: Ceccarelli, Sara, et al.
Publicado: (2013)

Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders
por: Turchinovich, Andrey, et al.
Publicado: (2018)

Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021)

Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
por: Sasaki, Ritsue, et al.
Publicado: (2019)

Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation
por: Da, Ben L., et al.
Publicado: (2020)

Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease
por: Tapper, Elliot B., et al.
Publicado: (2014)

Editorial: The heart of NAFLD
por: Chew, Nicholas W. S., et al.
Publicado: (2023)

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study
por: Curry, Michael P, et al.
Publicado: (2021)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
por: Di Mauro, Stefania, et al.
Publicado: (2019)

Stroke and Circulating Extracellular RNAs
por: Mick, Eric, et al.
Publicado: (2017)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

Identifying Autophagy-Related lncRNAs and Potential ceRNA Networks in NAFLD
por: Cao, Ziyi, et al.
Publicado: (2022)

Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors
por: Tiwari-Heckler, Shilpa, et al.
Publicado: (2018)

Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development
por: Kriss, Michael, et al.
Publicado: (2020)

Circulating Ism1 Reduces the Risk of Type 2 Diabetes but not Diabetes-Associated NAFLD
por: Wang, Jiajia, et al.
Publicado: (2022)

Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples
por: Jain, Sidhartha, et al.
Publicado: (2015)

NAFLD and COVID-19: a Pooled Analysis
por: Sachdeva, Sonali, et al.
Publicado: (2020)

NAFLD in the Elderly
por: Alqahtani, Saleh A, et al.
Publicado: (2021)

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program
por: Williams, RN, et al.
Publicado: (2016)

Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease
por: Miao, Zong, et al.
Publicado: (2021)

A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity
por: Hagemann, Christoffer A., et al.
Publicado: (2022)

Assessing the Differential Abundance of Maternal Circulating MicroRNAs or Interferon-Stimulated Genes with Early Pregnancy
por: DeCarlo, Andrea N., et al.
Publicado: (2023)

Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
por: Zhang, Chunye, et al.
Publicado: (2021)

The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)
por: Hanson, Amanda, et al.
Publicado: (2018)

Circulating miRNAs as Biomarkers for Mitochondrial Neuro-Gastrointestinal Encephalomyopathy
por: Mencias, Mark, et al.
Publicado: (2021)

Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD
por: Di Mauro, Stefania, et al.
Publicado: (2021)

The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC
por: Rusu, Ioana, et al.
Publicado: (2022)

Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance?
por: Shabani, Parisa, et al.
Publicado: (2015)

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD
por: Akuta, Norio, et al.
Publicado: (2019)

Circulating branch chain amino acids and improvement in liver fat content in response to exercise interventions in NAFLD
por: Shi, Xiulin, et al.
Publicado: (2021)

Current Management of NAFLD
por: MUNTEANU, MIHAI ALEXANDRU, et al.
Publicado: (2016)

Practice Guidelines on NAFLD
por: Palmer, Melissa
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ouh2pa3bb2ugs8jbtdta4oicvf